Raffaele Giusti1, Paolo Bossi2, Marco Mazzotta1, Marco Filetti1, Daniela Iacono3, Paolo Marchetti1. 1. Medical Oncology Unit, Sant'Andrea Hospital of Rome, Rome, Italy. 2. Medical Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. 3. Pulmonary Oncology Unit, San Camillo Forlanini Hospital, Rome, Italy.
Abstract
BACKGROUND: Head and neck (H&N) cancers account for about 5% of all malignant tumours. Pain is one of the most feared consequences of H&N neoplasms and is experienced by up to 80% of patients and worsens their quality of life inhibiting speaking, eating, drinking or swallowing. Nevertheless, pain is still often underestimated and undertreated. OBJECTIVES: The role of opioids in cancer pain has been well established but evidences about the role and the relative effectiveness of opioids such as fentanyl in the context of H&N cancer pain remains unclear. METHODS: A literature review based on the guidance of the Centre for Reviews and Dissemination was conducted. An iterative approach was used starting with an electronic search in the MEDLINE database. The search terms (('Neoplasms'[Mesh]) AND 'Head and Neck Neoplasms'[Mesh]) AND 'Fentanyl'[Mesh] were used. RESULTS: A total of 18 publications were found by the first performed search on PubMed. Other publications concordant with our aim were found by cross-reference. Considering inclusion and exclusion criteria for our review, eight papers resulted eligible for analysis. CONCLUSION: Fentanyl transdermal therapeutic system (TTS) seems to be an important option, thanks to the way of administration, the good safety and tolerability profiles to control baseline pain. For breakthrough cancer pain (BTcP), several formulations of transmucosal fentanyl are available. All the formulations seem to be active and safety but we lack head-to-head studies of fentanyl versus other strong opioids, as well as with different formulation of fentanyl, particularly for BTcP where H&N cancer population is very poorly represented.
BACKGROUND: Head and neck (H&N) cancers account for about 5% of all malignant tumours. Pain is one of the most feared consequences of H&N neoplasms and is experienced by up to 80% of patients and worsens their quality of life inhibiting speaking, eating, drinking or swallowing. Nevertheless, pain is still often underestimated and undertreated. OBJECTIVES: The role of opioids in cancer pain has been well established but evidences about the role and the relative effectiveness of opioids such as fentanyl in the context of H&N cancer pain remains unclear. METHODS: A literature review based on the guidance of the Centre for Reviews and Dissemination was conducted. An iterative approach was used starting with an electronic search in the MEDLINE database. The search terms (('Neoplasms'[Mesh]) AND 'Head and Neck Neoplasms'[Mesh]) AND 'Fentanyl'[Mesh] were used. RESULTS: A total of 18 publications were found by the first performed search on PubMed. Other publications concordant with our aim were found by cross-reference. Considering inclusion and exclusion criteria for our review, eight papers resulted eligible for analysis. CONCLUSION: Fentanyl transdermal therapeutic system (TTS) seems to be an important option, thanks to the way of administration, the good safety and tolerability profiles to control baseline pain. For breakthrough cancer pain (BTcP), several formulations of transmucosal fentanyl are available. All the formulations seem to be active and safety but we lack head-to-head studies of fentanyl versus other strong opioids, as well as with different formulation of fentanyl, particularly for BTcP where H&N cancer population is very poorly represented.
Entities:
Keywords:
Head and neck cancer; breakthrough pain; fentanyl; opioids; pain
Authors: Marie Fallon; Carlo Reale; Andrew Davies; A Eberhard Lux; Kirushna Kumar; Andrzej Stachowiak; Rafael Galvez Journal: J Support Oncol Date: 2011 Nov-Dec
Authors: R Mazzola; F Ricchetti; A Fiorentino; N Giaj-Levra; S Fersino; U Tebano; S Albanese; S Gori; F Alongi Journal: Clin Transl Oncol Date: 2016-11-16 Impact factor: 3.405
Authors: M H J van den Beuken-van Everdingen; J M de Rijke; A G Kessels; H C Schouten; M van Kleef; J Patijn Journal: Ann Oncol Date: 2007-03-12 Impact factor: 32.976
Authors: Angela W Miser; Prem K Narang; Judith A Dothage; Robert C Young; William Sindelar; James S Miser Journal: Pain Date: 1989-04 Impact factor: 6.961
Authors: J Haumann; J W Geurts; S M J van Kuijk; B Kremer; E A Joosten; M H J van den Beuken-van Everdingen Journal: Eur J Cancer Date: 2016-08-03 Impact factor: 9.162
Authors: Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg Journal: Radiother Oncol Date: 2003-03 Impact factor: 6.280
Authors: Marco Mazzotta; Marco Filetti; Marta Piras; Sebastiano Mercadante; Paolo Marchetti; Raffaele Giusti Journal: Cancer Manag Res Date: 2022-03-24 Impact factor: 3.989